Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 483

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 483
---
:

- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.

Services other than statutory audit provided by PricewaterhouseCoopers during 2024 comprised:

- contractual audits, including on the combined financial statements of the Opella business;

- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and

- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.

(d) Includes services provided by the independent auditors of the parent company and French subsidiaries: Forvis Mazars: € 0.1million in 2024 ,;

PricewaterhouseCoopers Audit € 3.5million in 2024 , € 3.6million in 2023 and Ernst & Young € 5.2million in 2023 .

(e) Includes € 0.5million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation

(which qualify as audit fees under SEC rules).

| F-100 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

F/ List of principal companies included in the scope

of consolidation during 2024

F.1. Principal fully consolidated companies

The table below shows Sanofi’s principal subsidiaries and their country of incorporation :

| Europe                                   |             | Financial interest (%) as ofDecember 31, 2024 |
|:-----------------------------------------|:------------|----------------------------------------------:|
| Hoechst GmbH *                           | Germany     |                                         100.0 |
| Sanofi-Aventis Deutschland GmbH          | Germany     |                                         100.0 |
| A. Nattermann & Cie GmbH                 | Germany     |                                         100.0 |
| Sanofi-Aventis GmbH                      | Austria     |                                         100.0 |
| Sanofi Belgium                           | Belgium     |                                         100.0 |
| Ablynx NV                                | Belgium     |                                         100.0 |
| Genzyme Flanders BV                      | Belgium     |                                         100.0 |
| Sanofi A/S                               | Denmark     |                                         100.0 |
| Sanofi-Aventis SA                        | Spain       |                                         100.0 |
| Opella Healthcare Spain, SL              | Spain       |                                         100.0 |
| Sanofi Oy                                | Finland     |                                         100.0 |
| Sanofi                                   | France      |                                         100.